Content area
Full Text
P E R S P E C T I V E S
5. La Revue Prescire Enqute. Mdicaments pour les maladies rares: bilan contrast en Europe Synthse labore collectivement par la Rdaction. La Revue Prescire 26, 781 (2006) (in French).
6. European Medicines Agency. COMP report to the Commission in relation to article 10 of regulation 141/2000 on orphan medicinal products. European Medicines Agency website [online], http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/04/WC500089638.pdf
Web End =http://www.ema. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/04/WC500089638.pdf
Web End =europa.eu/docs/en_GB/document_library/ http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/04/WC500089638.pdf
Web End =Report/2010/04/WC500089638.pdf (2005).
7. Heemstra H. H. From Research on rare diseases to new orphan drug development. Thesis, Utrecht Univ., Netherlands (2009).
8. Wellman-Labadie, O. & Zhou, Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 95, 216228 (2010).
9. CRA International. The current state of innovation in the pharmaceutical industry. European Federation of Pharmaceutical Industries and Associations website [online], http://www.efpia.org/content/default.asp?PageID=559&DocID=4896
Web End =http://www.efpia.org/content/default. http://www.efpia.org/content/default.asp?PageID=559&DocID=4896
Web End =asp?PageID=559&DocID=4896 (2008).
10. Paul, S. M. et al. How to improve R.&D productivity: the pharmaceutical industrys grand challenge. Nature Rev. Drug Discov. 9, 203214 (2010).
11. Joppi, J. et al. Orphan drug development is not taking off. Br. J. Clin. Pharm. 67, 494502 (2009).
12. Hirschhorn, R. & Reuser A. J. J. in The Metabolic & Molecular Bases of Inherited Diseases 8th edn (eds Scriver C. R. et al.) 3395 (McGraw-Hill, New York, 2001).
13. Genzyme Corporation. Genzyme annual report 2004. (Genzyme, Cambridge, Massachusetts, 2004).
14. Council of the European Union. Council Recommendation on action in the field of rare diseases. Council of the European Union website [online], http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/108383.pdf
Web End =http://www.consilium.europa.eu/uedocs/cms_ http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/108383.pdf
Web End =data/docs/pressdata/en/lsa/108383.pdf (2009).
15. The European Agency for the Evaluation of Medicinal Products. Status report on the implementation of the European Parliament legislation on orphan medicinal products. (EMEA, 2001).
16. European Commission. Register of designated Orphan Medicinal Products. The European Commission website [online], http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/community-register/html/orphreg.htm
Web End =http://ec.europa.eu/enterprise/ http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/community-register/html/orphreg.htm
Web End =sectors/pharmaceuticals/documents/community- http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/community-register/html/orphreg.htm
Web End =register/html/orphreg.htm (2010).
17. Alcimed. Study for the European Commission: Study on Orphan Drugs, Part I and Part II. European Commission website [online], http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf
Web End =http://ec.europa.eu/ http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf
Web End =health/files/orphanmp/doc/pricestudy/final_final_ http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf
Web End =report_part_1_web_en.pdf ; http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_2_web_en.pdf
Web End =http://ec.europa.eu/ http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_2_web_en.pdf
Web End =health/files/orphanmp/doc/pricestudy/final_final_ http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_2_web_en.pdf
Web End =report_part_2_web_en.pdf (2004).
18. Eichler H. -G. et al. Relative efficacy of...